Theater of the Absurd in J6 Courtrooms

Despite Crazy Revisions, Consumer Confidence Rebounds From January's Doom After Boomers and Gen X dragged The Conference Board Confidence measure down to eight month lows to end 2025, expectations were for a rebound to start 2026. Instead, January was a bloodbath with all the cohorts tumbling. Today sees February's data released with expectations for a rebound, particularly in expectations... and the consensus was right. The headline Consumer Confidence print rose from 84.5 (revised dramatically up to 89.0) to 91.2 (better than the 87.1 expected) Under the hood it was kind of crazy with the...

The current war is a timely reminder that the US ruling elites regard the US taxpayers and ordinary Americans as little more than inconvenient afterthoughts in US foreign policy.

Novo Nordisk Extends Slide After Announcing Price-Cuts For Blockbuster Obesity Drugs Novo Nordisk shares in Copenhagen can't catch a bid. The liquidation is accelerating again after a Bloomberg headline on Tuesday morning: the Danish drugmaker will slash U.S. list prices for Wegovy and Ozempic next year. The move suggests that the new CEO is pursuing market share amid intensifying competition in the GLP-1 space. Jamey Millar, Novo's head of U.S. operations, was quoted by Bloomberg as saying the company set a monthly price of $675 for its family of semaglutide drugs,...